% Expired Patents = 75.0

Forward Citations = 1

Loading Chart...

2 inventors (with patents filed for the assignee):

Samedy Ouk (4 out of 23 patents)

Hsiou-Chi Liou (4 out of 5 patents)

4 patents: Sort by Forward Citations

1. 11266648 - Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors (2022-03-08),

2. 11083729 - Methods of treating cancer with small molecule NF-κB inhibitors (2021-08-10),

3. 10660894 - Small molecule NF-κB inhibitors (2020-05-26),

4. 10226464 - Small molecule NF-κB inhibitors (2019-03-12),

Company Overview

Immunetarget, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and other diseases. Their proprietary technology platform allows for the targeted delivery of therapeutic agents to the immune system, enhancing the body's ability to fight off disease. With a team of world-class researchers and clinicians, Immunetarget is at the forefront of the burgeoning field of immunotherapy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

4 Patents

#3 in Medina, WA

#1,463 in Washington

#60,597 in US

Medina, WA, United States of America

Immunetarget, Inc.

Forward Citations = 1

2 inventors:

Samedy Ouk (4 out of 23 patents)

Hsiou-Chi Liou (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immunetarget, Inc.. Retrieved from https://idiyas.com/company/immunetarget

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]